Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of pharmacogenetics in cancer therapeutics.

Literature DB >> 16842377

The role of pharmacogenetics in cancer therapeutics.

Wei Peng Yong¹, Federico Innocenti, Mark J Ratain.

Abstract

The variability in treatment responses and narrow therapeutic index of anticancer drugs are some of the key challenges oncologists face. The knowledge of pharmacogenetics can potentially aid in the discovery, development and ultimately individualization of anticancer drugs. The identification of genetic variations that predict for drug response is the first step towards the translation of pharmacogenetics into clinical practice. This review provides an update on the results of studies assessing the effects of germline polymorphisms and somatic mutations on therapeutic outcomes and highlights the potential applications and future challenges in pharmacogenetic research pertaining to cancer therapeutics.

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 16842377 PMCID： PMC1885075 DOI： 10.1111/j.1365-2125.2006.02591.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

130 in total

1. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis.

Authors: Simon Cronin; Karen L Furie; Peter J Kelly
Journal: Stroke Date: 2005-06-09 Impact factor: 7.914

2. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

Authors: Toshimi Takano; Yuichiro Ohe; Hiromi Sakamoto; Koji Tsuta; Yoshihiro Matsuno; Ukihide Tateishi; Seiichiro Yamamoto; Hiroshi Nokihara; Noboru Yamamoto; Ikuo Sekine; Hideo Kunitoh; Tatsuhiro Shibata; Tokuki Sakiyama; Teruhiko Yoshida; Tomohide Tamura
Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544

3. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Authors: Susan A Nowell; Jiyoung Ahn; James M Rae; Joshua O Scheys; Andrew Trovato; Carol Sweeney; Stewart L MacLeod; Fred F Kadlubar; Christine B Ambrosone
Journal: Breast Cancer Res Treat Date: 2005-06 Impact factor: 4.872

Review 4. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Authors: Román Peréz-Soler; Leonard Saltz
Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544

5. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors: Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal: J Natl Cancer Inst Date: 2005-05-04 Impact factor: 13.506

6. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506

7. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors: R M Weinshilboum; S L Sladek
Journal: Am J Hum Genet Date: 1980-09 Impact factor: 11.025

8. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.

Authors: Kazumi Uchida; Kazuhiko Hayashi; Kazuyuki Kawakami; Sylke Schneider; Ji Min Yochim; Hidekazu Kuramochi; Ken Takasaki; Kathleen D Danenberg; Peter V Danenberg
Journal: Clin Cancer Res Date: 2004-01-15 Impact factor: 12.531

9. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.

Authors: G D Heggie; J P Sommadossi; D S Cross; W J Huster; R B Diasio
Journal: Cancer Res Date: 1987-04-15 Impact factor: 12.701

10. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Authors: Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren
Journal: Breast Cancer Res Date: 2005-01-28 Impact factor: 6.466

23 in total

1. The role of pharmacogenetics and pharmacogenomics in improving translational medicine.

Authors: Willard H Dere; Tamas S Suto
Journal: Clin Cases Miner Bone Metab Date: 2009-01

2. Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.

Authors: L D Lewis
Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335

3. Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors: Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal: Trends Cancer Res Date: 2008

Review 4. Clinical pharmacology--providing tools and expertise for translational medicine.

Authors: J K Aronson; A Cohen; L D Lewis
Journal: Br J Clin Pharmacol Date: 2008-02 Impact factor: 4.335

Review 5. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

Authors: Peter H O'Donnell; Walter M Stadler
Journal: Clin Cancer Res Date: 2012-03-16 Impact factor: 12.531

6. The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.

Authors: Suayib Yalçin
Journal: Gastrointest Cancer Res Date: 2009-09

Review 7. Institutional shared resources and translational cancer research.

Authors: Paolo De Paoli
Journal: J Transl Med Date: 2009-06-29 Impact factor: 5.531

8. Integrating Epigenomics into Pharmacogenomic Studies.

Authors: Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal: Pharmgenomics Pers Med Date: 2008-11

Review 9. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors: Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal: World J Gastroenterol Date: 2016-07-14 Impact factor: 5.742

10. Role of pharmacogenomics in drug discovery and development.

Authors: A Surendiran; S C Pradhan; C Adithan
Journal: Indian J Pharmacol Date: 2008-08 Impact factor: 1.200